Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Claytons research contributions to PT-141 development include: Principal investigator for pivotal Phase 2 dose-finding trial establishing optimal 1.75 mg dose Lead investigator for RECONNECT Phase 3 trials supporting FDA approval Development of responder analysis methodology for patient-reported outcomes in sexual dysfunction Neurobehavioral research elucidating central mechanisms of sexual desire Extensive publication record on bremelanotide efficacy, safety, and clinical applications Her work has established PT-141 as the second FDA-approved pharmacological treatment for HSDD and the first melanocortin-based therapy for sexual dysfunction, representing a significant advance in womens sexual health treatment options
Manou D, et al
10.1073/pnas.0606714103 116 WylieL
Benefits of FB Nutrition L-Arginine + L-Citrulline
US$ 27.66
US$ 24.05
US$ 27.88
